ERBB2 and breast cancer: It has been previously shown that HER2-mediated downstream oncogenic signaling in BC cells is activated by nuclear translocation of the truncated receptor tyrosine kinase (RTK) p95 intracellular soluble domain (i.e., p95HER2, named HER2-ICD) [44, 45].